On May 25, 2017 TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, reported the presentation of three ZEJULA (niraparib) abstracts at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, June 2 to June 6, 2017, in Chicago (Press release, TESARO, MAY 25, 2017, View Source [SID1234519300]). In addition, TESARO will host an investor and analyst briefing in Chicago on Saturday, June 3 at 6:00 PM local time in conjunction with the ASCO (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re excited to see presentations of additional data from the landmark ENGOT-OV16/NOVA trial presented at this year’s ASCO (Free ASCO Whitepaper) Annual Meeting," said Mary Lynne Hedley, Ph.D., President and COO, TESARO. "We also look forward to sharing initial data from the TOPACIO trial of niraparib plus pembrolizumab, as well as data from the Phase 1 trial of TSR-042, our anti-PD-1 antibody, at our ASCO (Free ASCO Whitepaper) investor briefing."

Please plan to visit TESARO at Booth #18097 to learn more about ZEJULA (niraparib), VARUBI (rolapitant) and our immuno-oncology pipeline.

Presentation Details:

Saturday, June 3, 2017, 1:15 PM to 4:45PM
Efficacy of Niraparib on Progression-free Survival (PFS) in Patients (Pts) with Recurrent Ovarian Cancer (OC) with Partial Response to the Last Platinum-based Chemotherapy
Abstract #5517, Poster Board #339, Location: Hall A
Poster Discussion: Saturday, June 3, 2017, 4:45 PM to 6:00 PM, Location: Aerie Crown Theater

Saturday, June 3, 2017, 1:15 PM to 4:45PM
Long-Term Benefit of Niraparib Treatment of Recurrent Ovarian Cancer (OC)
Abstract #5534, Poster Board #356, Location: Hall A

Saturday, June 3, 2017, 1:15 PM to 4:45PM
The Successful Phase 3 Niraparib ENGOT-OV16/NOVA Trial Included a Substantial Number of Patients with Platinum Resistant Ovarian Cancer
Abstract #5560, Poster Board #382, Location: Hall A